BCRX BioCryst Pharmaceuticals Inc.

+0.01  (+0%)
Previous Close 2.58
Open 2.59
Price To Book -32.38
Market Cap 286,035,521
Shares 110,438,425
Volume 1,743,042
Short Ratio
Av. Daily Volume 1,547,560

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
Phase 3 trial to commence 2020.
Angioedema attacks in patients with hereditary angioedema (HAE)
NDA filing due 4Q 2019.
BCX7353 - APeX-2
Reduce or eliminate attacks in HAE patients
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
RAPIVAB (peramivir)
Dosing of first patient in long-term safety trial announced February 28, 2018.
BCX7353 - APeX-S
Hereditary angioedema (HAE)
Phase 1 trial completion announced May 9, 2019. Generally safe and well tolerated.
Healthy volunteers
Phase 1 data due 4Q 2019.
Healthy subjects
Phase 1 trial to commence 2H 2019.
Fibrodysplasia ossificans progressiva (FOP)

Latest News

  1. Edited Transcript of BCRX earnings conference call or presentation 6-Aug-19 12:30pm GMT
  2. Biocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript
  3. BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates
  4. BioCryst Reports Second Quarter 2019 Financial Results
  5. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
  6. Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline
  7. BioCryst to Report Second Quarter 2019 Financial Results on August 6
  8. BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  9. BioCryst Appoints Megan Sniecinski Chief Business Officer
  10. Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
  11. Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT
  12. BioCryst to Present at Upcoming Investor Conferences
  13. Here's Why BioCryst Pharmaceuticals Is Soaring Today
  14. The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study
  15. Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today
  16. In less than six hours today, this Durham company's stock has dropped 50 percent
  17. Here's Why BioCryst Pharmaceuticals Collapsed Today
  18. BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial